UCB SA Asset Resilience Ratio
UCB SA asset resilience ratio. UCB SA (UCB) has an Asset Resilience Ratio of 0.15% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read UCB total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of UCB SA (2000–2025)
Asset resilience ratio of UCB SA from 2000 to 2025. This chart shows how UCB SA's Asset Resilience Ratio has changed over time. See UCB SA free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down UCB SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see UCB SA asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €31.00 Million | 0.15% |
| Total Liquid Assets | €31.00 Million | 0.15% |
Asset Resilience Insights
- Limited Liquidity: UCB SA maintains only 0.15% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
UCB SA Industry Peers by Asset Resilience Ratio
Compare UCB SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Achieve Life Sciences Inc
NASDAQ:ACHV |
Biotechnology | 3.60% |
|
Alpha Tau Medical Ltd
NASDAQ:DRTS |
Biotechnology | 65.79% |
|
Pulike Biological Engineering
SHG:603566 |
Biotechnology | 17.82% |
UCB SA Asset Resilience Ratio by Year (2000–2025)
UCB SA asset resilience ratio by year from 2000 to 2025. The table below shows the annual Asset Resilience Ratio data for UCB SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.21% | €219.00 Million ≈ $256.03 Million |
€18.16 Billion ≈ $21.23 Billion |
+0.15pp |
| 2024-12-31 | 1.06% | €184.00 Million ≈ $215.12 Million |
€17.35 Billion ≈ $20.28 Billion |
+0.37pp |
| 2023-12-31 | 0.70% | €108.00 Million ≈ $126.26 Million |
€15.54 Billion ≈ $18.17 Billion |
-0.38pp |
| 2022-12-31 | 1.07% | €170.00 Million ≈ $198.75 Million |
€15.87 Billion ≈ $18.55 Billion |
+0.30pp |
| 2021-12-31 | 0.77% | €110.00 Million ≈ $128.60 Million |
€14.21 Billion ≈ $16.61 Billion |
-4.51pp |
| 2020-12-31 | 5.29% | €704.00 Million ≈ $823.05 Million |
€13.32 Billion ≈ $15.57 Billion |
-3.64pp |
| 2019-12-31 | 8.93% | €989.00 Million ≈ $1.16 Billion |
€11.08 Billion ≈ $12.95 Billion |
+8.76pp |
| 2018-12-31 | 0.16% | €17.00 Million ≈ $19.87 Million |
€10.51 Billion ≈ $12.29 Billion |
+0.02pp |
| 2017-12-31 | 0.14% | €14.00 Million ≈ $16.37 Million |
€9.92 Billion ≈ $11.59 Billion |
-0.31pp |
| 2016-12-31 | 0.45% | €46.00 Million ≈ $53.78 Million |
€10.21 Billion ≈ $11.94 Billion |
+0.14pp |
| 2015-12-31 | 0.31% | €34.00 Million ≈ $39.75 Million |
€10.96 Billion ≈ $12.81 Billion |
+0.30pp |
| 2014-12-31 | 0.01% | €1.00 Million ≈ $1.17 Million |
€10.15 Billion ≈ $11.86 Billion |
0.00pp |
| 2013-12-31 | 0.01% | €1.00 Million ≈ $1.17 Million |
€9.76 Billion ≈ $11.41 Billion |
-0.08pp |
| 2012-12-31 | 0.09% | €8.00 Million ≈ $9.35 Million |
€9.36 Billion ≈ $10.94 Billion |
-0.33pp |
| 2011-12-31 | 0.41% | €38.00 Million ≈ $44.43 Million |
€9.18 Billion ≈ $10.73 Billion |
-0.27pp |
| 2010-12-31 | 0.68% | €61.00 Million ≈ $71.32 Million |
€8.97 Billion ≈ $10.49 Billion |
+0.10pp |
| 2009-12-31 | 0.58% | €53.00 Million ≈ $61.96 Million |
€9.12 Billion ≈ $10.66 Billion |
+0.55pp |
| 2008-12-31 | 0.03% | €3.00 Million ≈ $3.51 Million |
€9.52 Billion ≈ $11.13 Billion |
-0.97pp |
| 2007-12-31 | 1.00% | €96.00 Million ≈ $112.23 Million |
€9.55 Billion ≈ $11.17 Billion |
-6.45pp |
| 2004-12-31 | 7.45% | €400.36 Million ≈ $468.06 Million |
€5.37 Billion ≈ $6.28 Billion |
-4.17pp |
| 2003-12-31 | 11.62% | €359.05 Million ≈ $419.77 Million |
€3.09 Billion ≈ $3.61 Billion |
-4.44pp |
| 2002-12-31 | 16.05% | €420.73 Million ≈ $491.88 Million |
€2.62 Billion ≈ $3.06 Billion |
+2.83pp |
| 2001-12-31 | 13.22% | €339.05 Million ≈ $396.39 Million |
€2.56 Billion ≈ $3.00 Billion |
+1.63pp |
| 2000-12-31 | 11.59% | €266.93 Million ≈ $312.07 Million |
€2.30 Billion ≈ $2.69 Billion |
-- |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, … Read more